Clinical trialNCT05571059RecruitingPhase 2Interventional

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

SponsorCumberland PharmaceuticalsEnrollment128Idiopathic Pulmonary Fibrosis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Todd Rice, MD, MSc
Cumberland Pharmaceuticals
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Biosolutions Clinical Research
La Mesa, California, United States
Kaveh Bagheri, MD
Recruiting
University of California San Francisco
San Francisco, California, United States
Jeffrey Golden, MD
Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
Augustine Lee, MD
Recruiting
Miami Va Health System
Miami, Florida, United States
Robert Jackson, MD
Recruiting
Northwestern Medicine
Chicago, Illinois, United States
Krishnan Warrior, MD
Recruiting
Indiana University Health
Indianapolis, Indiana, United States
Damien Patel, MD
Recruiting
University of Kansas
Kansas City, Kansas, United States
Mark Hamblin, MD
Recruiting
University of Louisville
Louisville, Kentucky, United States
Mohamed Saad, MD
Recruiting
Beaumont Hospital, Royal Oak
Royal Oak, Michigan, United States
Enrique Calvo-Ayala, MD
Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Maria Padilla, MD
Recruiting
University of Rochester
Rochester, New York, United States
David Nagel, MD, PhD
Recruiting
Unc Chapel Hill
Chapel Hill, North Carolina, United States
Recruiting
Bend Memorial Hospital
Bend, Oregon, United States
Jeremy Feldman, MD
Recruiting
Temple University Hospital
Philadelphia, Pennsylvania, United States
Gerard Criner, MD
Recruiting
Avera Research Institute
Sioux Falls, South Dakota, United States
Fady Jamous, MD
Recruiting
Pulmonary & Sleep Specialists
Dickson, Tennessee, United States
Mohammad Alsoub, MD
Recruiting
Baylor University Medical Center
Dallas, Texas, United States
Susan Mathai, MD
Recruiting
Premier Pulmonary Critical Care and Sleep Medicine
Denison, Texas, United States
Sanober Kable, MD
Recruiting
Uw Health University Hospital
Madison, Wisconsin, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ifetroban SodiumPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jan 2024
Primary completion: 31 Jan 2027
Completion: 31 Jan 2027
Last update posted: 5 Mar 2026
Registered enrollment: 128
Registry id: NCT05571059

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.